SCHEMBL13511558

SCHEMBL13511558

COc1cc(-c2ccccc2)c2ccccc2c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACACA Q13085 2/20 0.50
▸ HK2 P52789 1/20 0.50
▸ MGAM O43451 6/20 0.46
▸ GAA P10253 6/20 0.46
▸ SI P14410 6/20 0.46
▸ MGAM2 Q2M2H8 6/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PDE4B Q07343 4/20 0.45
▸ PDE4A P27815 3/20 0.45
▸ PDE4C Q08493 3/20 0.45
▸ PDE4D Q08499 3/20 0.45
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPT P10636 1/20 0.41
▸ GPR84 Q9NQS5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26259484 0.87 KDM4E (0.51) ACACAHK2HPGDSMN1; SMN2MEN1
SCHEMBL26259454 0.86 SQOR (0.43) ACACAMGAMGAASIMGAM2
SCHEMBL14981133 0.82 ACACA (0.46) ACACAHK2MGAMGAASI
SCHEMBL26259615 0.81 MEN1 (0.47) ACACAGAALMNAHPGDSMN1; SMN2
SCHEMBL28384098 0.80 ALOX5 (0.44) SMN1; SMN2NPC1RAB9AMAPTGPR84
SCHEMBL26259629 0.79 MAPT (0.52) LMNAHPGDSMN1; SMN2PDE4BPDE4A
SCHEMBL24049723 0.79 PGR (0.56) ACACAHK2GAALMNAHPGD
Terferol SCHEMBL30545089 0.78 MGAM (0.75) HK2MGAMGAASIMGAM2
SCHEMBL14027797 0.77 PGR (0.54) ACACAHK2SMN1; SMN2MEN1NPC1
SCHEMBL20970991 0.76 MAPT (0.48) ACACALMNAHPGDSMN1; SMN2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2023-09-14 — — US disclosed
US-20100039684-A1 SENSITIZER DYES FOR PHOTOACID GENERATING SYSTEMS USING SHORT VISIBLE WAVELENGTHS FORCETEC CO., LTD. (KR) 2010-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287262-A1 PHOTON UPCONVERSION COMPOSITION, FILM, METHOD FOR CONVERTING VISIBLE LIGHT INTO ULTRAVIOLET LIGHT, AND COMPOUND NUDC, CCNL2, SPIN3 ACACA 2047/4885HK2 4119/4885MGAM 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback